Updates are available Correction dated 2025-08-13
Click to view Correction: https://doi.org/10.1007/s40123-025-01224-w
-
Authors
Khodor, Ali https://orcid.org/0009-0004-8752-919X
Caranfa, Jonathan T.
Nanda, Tavish
Ruiz-Lozano, Raul E. https://orcid.org/0000-0001-7022-2395
Quiroga-Garza, Manuel E. https://orcid.org/0000-0002-5237-240X
Choi, Stephanie
Chehab, Ali
Ramos-Dávila, Eugenia M.
Heier, Jeffrey S.
Shah, Chirag P. https://orcid.org/0000-0001-6369-4917
Witkin, Andre J. https://orcid.org/0000-0002-3001-8098
- License Information
-
More Information
Article History
Received: 29 April 2025
Accepted: 27 May 2025
First Online: 3 July 2025
Change Date: 15 August 2025
Change Type: Update
Change Details: The original online version of this article was revised due to given name of the author Jeffrey S. Heier was incorrectly published as Jeffery S. Heier. Now, the author name has been corrected
Change Date: 13 August 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40123-025-01224-w
Declarations
:
: Chirag Shah is a consultant and clinical trialist for Genentech. Andre Witkin is a consultant and primary investigator for Genentech and Apellis and an Editorial Board member of Ophthalmology and Therapy. Andre Witkin was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Jeffrey Heier is a consultant for: 4DMT, Abbvie/Regenxbio, Abpro, Affamed, Alkeus, Annexon, Asclepix, Aviceda, Bayer, Beacon, Boehringer Ingleheim, Breye Therapeutics, Caeregen, Cogent, Complement Therapeutics, Curacle, Daiichi Sankyo, Emmetrope, Endogena, Frontera, Galimedix, Inflammx, Kaigene, Kanghong, Lilly, Manistee, Nanoscope, Notal Vision, Novartis, Ocuphire, OcuTerra, Opthea, Osanni, Ray Therapeutics, Regeneron, Samsung Bioepis, Sanofi, Skyline, Stealth, Laboratoires Thea, Unity Bio, Vanotech, and Visgenx; member of DSMC: Akouos; employee/executive: Chief Scientific Officer: Ocular Therapeutix; research investigator: 4DMT, Abbvie/Regenxbio, Annexon, Apellis, Astellas, Bayer, Beacon, Boehringer Ingleheim, Cognition Therapeutics, Curacle, Genentech/Roche, Janssen R&D, Kodiak, Notal Vision, Novartis, Oculis, Opthea, Perceive Bio, Regeneron, Sanofi, Skyline, Stealth Biotherapeutics, and Vanotech; holds equity in: Adverum, Aldeyra, Alzheon, Aviceda, Caeregen, Inflammx, jCyte, Manistee, Ocuphire, Ocular Therapeutix, Osanni Bio, Ray Therapeutics, RevOpsis, Vinci, Visgenx, and Vitranu. Ali Khodor, Jonathan T. Caranfa, Tavish Nanda, Raul E. Ruiz-Lozano, Manuel E. Quiroga-Garza, Stephanie Choi, Ali Chehab, and Eugenia M. Ramos-Dávila declare no conflicts of interest.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
